Back to Report Store Home

Non-Small Cell Lung Cancer Market to 2020 – New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

  • Published: Jul-2014
  • Report Code: GBIHC338MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Non-Small Cell Lung Cancer Market, Global, Molecular Characteristic Frequency (%), 2014

Figure 2: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Late-Stage Treatment Algorithm, 2014

Figure 3: Non-Small Cell Lung Cancer Market, Global, Squamous Late-Stage Treatment Algorithm, 2014

Figure 4: NSCLC, Global, Marketed Products Heatmap, 2013

Figure 5: Non-Small Cell Lung Cancer, Global, Pipeline Summary, 2014

Figure 6: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Overview, 2014

Figure 7: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Breakdown, 2014

Figure 8: Non-Small Cell Lung Cancer, Global, Clinical Trial Attrition Rates (%), 2006–2014

Figure 9: Non-Small Cell Lung Cancer, Global, Clinical Trial Mechanism of Action Failure Rates by Phase (%), 2006–2014

Figure 10: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration (months), 2006–2013

Figure 11: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Molecule Type (months), 2006–2013

Figure 12: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Mechanism of Action (months), 2006–2013

Figure 13: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product (participants), 2006–2013

Figure 14: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2013

Figure 15: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Mechanism of Action (months), 2006–2013

Figure 16: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoints, 2006–2013

Figure 17: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoint Combinations by Phase (%), 2006–2013

Figure 18: Non-Small Cell Lung Cancer Pipeline, Global, Custirsen Annual Sales ($m), 2018–2020

Figure 19: Non-Small Cell Lung Cancer Pipeline, Global, Halaven Annual Sales ($m), 2016–2020

Figure 20: Non-Small Cell Lung Cancer Pipeline, Global, Dacomitinib Annual Sales ($m), 2014–2020

Figure 21: Non-Small Cell Lung Cancer Pipeline, Global, Vargatef Annual Sales ($m), 2015–2020

Figure 22: Non-Small Cell Lung Cancer Pipeline, Global, Necitumumab Annual Sales ($m), 2015–2020

Figure 23: Non-Small Cell Lung Cancer Pipeline, Global, Ganetespib Annual Sales ($m), 2016–2020

Figure 24: Non-Small Cell Lung Cancer Pipeline, Global, Zykadia Annual Sales ($m), 2014–2020

Figure 25: Non-Small Cell Lung Cancer Pipeline, Global, Yervoy Annual Sales ($m), 2015–2020

Figure 26: Non-Small Cell Lung Cancer Pipeline, Global, Nivolumab Annual Sales ($m), 2015–2020

Figure 27: Non-Small Cell Lung Cancer Pipeline, Global, Cyramza Annual Sales ($m), 2015–2020

Figure 28: Non-Small Cell Lung Cancer Pipeline, Global, Tavocept Annual Sales ($m), 2017–2020

Figure 29: Non-Small Cell Lung Cancer Pipeline, Global, Tertomotide Annual Sales ($m), 2017–2020

Figure 30: Non-Small Cell Lung Cancer Pipeline, Global, Lucanix Annual Sales ($m), 2016–2020

Figure 31: Non-Small Cell Lung Cancer , Global, Safety and Efficacy Heatmap, 2013

Figure 32: Non-Small Cell Lung Cancer , Global, Marketed Products Heatmap, 2013

Figure 33: Non-Small Cell Lung Cancer Market, Global, Product Competitiveness Framework, 2014

Figure 34: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Future Treatment Algorithm 2020

Figure 35: Non-Small Cell Lung Cancer Market, Global, Squamous Future Treatment Algorithm

Figure 36: Non-Small Cell Lung Cancer Market, Global, Treatment Patterns (‘000), 2013–2020

Figure 37: Non-Small Cell Lung Cancer Market, Global, Market Size ($bn), 2013–2020

Figure 38: Non-Small Cell Lung Cancer Market, North America, Treatment Usage Patterns (‘000), 2013–2020

Figure 39: Non-Small Cell Lung Cancer Market, North America, Annual Cost of Treatment ($), 2013–2020

Figure 40: Non-Small Cell Lung Cancer Market, North America, Market Size, 2013–2020

Figure 41: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020

Figure 42: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020

Figure 43: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Market Size ($m), 2013–2020

Figure 44: Non-Small Cell Lung Cancer Market, Japan, Treatment Usage Patterns (‘000), 2013–2020

Figure 45: Non-Small Cell Lung Cancer Market, Japan, Annual Cost of Treatment ($), 2013–2020

Figure 46: Non-Small Cell Lung Cancer Market, Japan, Market Size ($bn), 2013–2020

Figure 47: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Region, 2006–2014

Figure 48: Non-Small Cell Lung Cancer, Global, Number of Co-Development Deals, 2006–2014

Figure 49: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Phase, 2006–2014

Figure 50: Non-Small Cell Lung Cancer, Global, Licensing Deals by Region, 2006–2014

Figure 51: Non-Small Cell Lung Cancer, Global, Number of Licensing Deals, 2006–2014

Figure 52: Non-Small Cell Lung Cancer, Global, Licensing Deals by Phase, 2006–2014

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards